سعر ميرونيم 1جم فيال للحقن الوريدي 2024

Meropenem 1 g (as trihydrate) powder for solution for intravenous injection or infusion, 1 vial (Meronem).

• Severe pneumonia, including hospital-acquired and ventilator-associated pneumonia.Population: Adults and children aged 3 months and olderEgyptian Drug Authority (EDA) e-services
• Broncho-pulmonary infections in cystic fibrosis.Population: Adults and children aged 3 months and olderEgyptian Drug Authority (EDA) e-services
• Complicated urinary tract infections.Population: Adults and children aged 3 months and olderEgyptian Drug Authority (EDA) e-services

• Common: thrombocythaemia, headache, diarrhoea, abdominal pain, vomiting, nausea, increased transaminases/alkaline phosphatase/LDH, rash, pruritus, injection-site inflammation and pain.Egyptian label · Egyptian Drug Authority (EDA) e-services
• Uncommon: oral and vaginal candidiasis, agranulocytosis, haemolytic anaemia, thrombocytopenia, neutropenia, leukopenia, eosinophilia, anaphylaxis, angioedema, paraesthesia, antibiotic-associated colitis, increased bilirubin, TEN, SJS, erythema multiforme, urticaria, increased creatinine and urea, thrombophlebitis; rare: delirium, convulsions.Egyptian label · Egyptian Drug Authority (EDA) e-services

• Hypersensitivity to meropenem or any excipient.Egyptian label · Egyptian Drug Authority (EDA) e-services
• Hypersensitivity to any other carbapenem antibacterial agent.Egyptian label · Egyptian Drug Authority (EDA) e-services
• Severe hypersensitivity (e.g. anaphylaxis, severe skin reaction) to any other type of beta-lactam antibacterial (e.g. penicillins or cephalosporins).Egyptian label · Egyptian Drug Authority (EDA) e-services

• Serious and occasionally fatal hypersensitivity reactions; ask about previous beta-lactam allergy before starting and stop if a severe reaction occurs.Egyptian label · Egyptian Drug Authority (EDA) e-services
• Severe cutaneous adverse reactions (SJS, TEN, DRESS, erythema multiforme, AGEP) have been reported; withdraw immediately if suspected.Egyptian label · Egyptian Drug Authority (EDA) e-services
• Antibiotic-associated and pseudomembranous colitis may occur; consider in patients with diarrhoea during or after treatment.Egyptian label · Egyptian Drug Authority (EDA) e-services

• ProbenecidProbenecid competes for tubular secretion and increases meropenem half-life and plasma concentration; use caution if co-administered.Egyptian Drug Authority (EDA) e-services
• Valproic acid / sodium valproate / valpromideCarbapenems reduce valproic acid levels by 60-100% within about two days; co-administration should be avoided.Egyptian Drug Authority (EDA) e-services
• Warfarin and other oral anticoagulantsAntibiotics may augment the anticoagulant effect; monitor INR frequently during and shortly after co-administration.Egyptian Drug Authority (EDA) e-services

• There are no or limited data in pregnant women; animal studies do not indicate harmful reproductive effects; as a precaution it is preferable to avoid use during pregnancy.Egyptian label · Egyptian Drug Authority (EDA) e-services
• Small amounts are excreted in human milk; should not be used in breast-feeding women unless the potential benefit justifies the potential risk to the baby.Egyptian label · Egyptian Drug Authority (EDA) e-services

English text not available for this section.

Do not store above 30°C.